{"schema_version":"secwatch.filing_event.v1","accession":"0001438133-21-000194","form_type":"8-K","ticker":"TNDM","cik":"0001438133","company_name":"TANDEM DIABETES CARE INC","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.591121+00:00","generated_at":"2026-06-28T13:50:55.096175+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tandem Diabetes Q3 sales $179.6M (+45% YoY); raises FY2021 sales guidance to $685-695M","bullets":["Q3 sales $179.6M (+45% YoY); net income $5.8M vs loss $9.4M; adjusted EBITDA $26.9M (15% of sales).","Worldwide pump shipments up 43% to 31,558; international shipments up 209% to 11,262.","Full-year 2021 sales guidance raised to $685-695M from $670-685M; international guidance raised to $168-173M.","Cash balance $595M, up $110M since Dec 2020; gross margin improved to 54% from 53%.","Virtual R&D Day scheduled for December 6, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001438133-21-000194","json":"https://secwatch.observer/filing/0001438133-21-000194.json","markdown":"https://secwatch.observer/filing/0001438133-21-000194.md","text":"https://secwatch.observer/filing/0001438133-21-000194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438133/000143813321000194/0001438133-21-000194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438133/000143813321000194/tndm-20211103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:50:55.096175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}